1032349-99-7

Basic information

• Product Name: CarbaMic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-diMethylethyl ester;tert-butyl 1-(4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl)cyclobutylcarbamate
• CAS NO: 1032349-99-7
• Molecular Formula: C₂₉H₂₈ClN₃O₂
• Molecular Weight: 486.00452
• Mol File: 1032349-99-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CarbaMic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-diMethylethyl ester(1032349-99-7)
• EPA Substance Registry System: CarbaMic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-diMethylethyl ester(1032349-99-7)

Safety Data

• Hazardous Substances Data: 1032349-99-7(Hazardous Substances Data)

Usage

Uses

N-[1-[4-(5-Chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]carbamic Acid 1,1-Dimethylethyl Ester is used as a reactant in the synthesis of diphenyl substituted naphthyridine compounds as inhibitors of Akt activity.

Upstream product

• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 
• 338452-92-9 4-amino-2-chloronicotinaldehyde 
• 1032349-97-5 tert-butyl[1-(4-cyanophenyl)cyclobutyl]carbamate 
• 1032349-98-6 tert-butyl 1-(4-(2-phenylacetyl)phenyl)cyclobutylcarbamate 
• 1032350-07-4 4-amino-2-chloronicotinaldehyde trifluoroacetate 

Downstream Products

• 1032350-03-0 tert-butyl {1-[4-(3-hydroxy-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]cyclobutyl}carbamate 
• 1032350-00-7 tert-butyl {1-[4-(5-hydrazino-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl}carbamate 
• 1238324-04-3 tert-butyl {1-[4-(5-methyl-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl}carbamate 
• 1238320-21-2 1-[4-(5-ethenyl-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutanamine 
• 1238320-23-4 2-{2-[4-(1-aminocyclobutyl)phenyl]-3-phenyl-1,6-naphthyridin-5-yl}ethanol 
• 1238316-58-9 2-[4-(1-aminocyclobutyl)phenyl]-6-(difluoromethyl)-3-phenyl-1,6-naphthyridin-5(6H)-one 
• 1238323-95-9 1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutanamine 
• 1238316-46-5 1-[4-(5-oxo-3-phenyl-5,6-dihydro-1,6-naphthyridin-2-yl)phenyl]cyclobutanaminium chloride 

Relevant articles and documents

IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS

The present invention provides methods for use of interleukin-23 (IL-23) antagonists to treat or prevent skin rash associated with treatment with PI3K/AKT pathway inhibitors, such as treatment of cancer.

Inhibitors of Akt activity

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.